CPR Stock Analysis: Davide Campari-Milano | MI

Beverages - Wineries & Distilleries | MI, Italy | Market Cap: 7.223m EUR | 12M Return: 5.9% | NL0015435975 | Charts, Fundamentals & Technical Analysis

Aperitifs, Spirits, Vodka, Champagne
Total Rating 62
Safety 83
Buy Signal 0.28
Beverages - Wineries & Distilleries
Industry Rotation: -13.6
Market Cap: 8.29B
Avg Turnover: 25.9M
Risk 3d forecast
Volatility33.0%
VaR 5th Pctl5.15%
VaR vs Median-4.60%
Reward TTM
Sharpe Ratio0.24
Rel. Str. IBD46.4
Rel. Str. Peer Group58
Character TTM
Beta-0.274
Beta Downside-0.446
Hurst Exponent0.392
Drawdowns 3y
Max DD55.08%
CAGR/Max DD-0.33
CAGR/Mean DD-0.49
EPS (Earnings per Share) EPS (Earnings per Share) of CPR over the last years for every Quarter: "2021-09": null, "2021-12": null, "2022-03": null, "2022-06": 0.08, "2022-09": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": null, "2024-03": null, "2024-06": null, "2024-09": null, "2024-12": 0.08, "2025-03": null, "2025-06": null, "2025-12": null, "2026-06": null,
Qual. Beats: 0
Revenue Revenue of CPR over the last years for every Quarter: 2021-09: 574.8, 2021-12: 1086.35, 2022-03: 534.8, 2022-06: 1348.8, 2022-09: 748.8, 2022-12: 1348.8, 2023-03: 667.9, 2023-06: 1457.8, 2023-09: 743.5, 2023-12: 1460.8, 2024-03: 663.5, 2024-06: 1523.4, 2024-09: 753.6, 2024-12: 1546.4, 2025-03: 665.6, 2025-06: 1527.9, 2025-12: 1523.2, 2026-06: 1512,
Rev. CAGR: 7.77%
Rev. Trend: 86.3%
Last SUE: 2.01
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan -2.2% 18
Feb +0.5% 19
Mar +0.4% 17
Apr +0.9% 21
May +1.6% 17
Jun -0.2% 7
Jul +0.8% 17
Aug +0.3% 11
Sep -4.4% 31
Oct -4.1% 40
Nov -1.0% 2
Dec -1.8% 51

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: CPR Davide Campari-Milano

Davide Campari-Milano N.V. (CPR) is a global beverage company producing and distributing alcoholic and non-alcoholic drinks across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Founded in 1860 and headquartered in Sesto San Giovanni, Italy, the company operates as a subsidiary of Lagfin S.C.A.

Classified within the Consumer Staples sector under Distillers & Vintners, Campari runs a multi-category brand portfolio spanning aperitifs, vodka, whisky, rum, agave-based spirits, cognac, and champagne. Flagship labels include Campari, Aperol, Wild Turkey, Appleton Estate, Grand Marnier, Courvoisier, and SKYY Vodka, alongside numerous regional and specialty brands such as SKYY, Bulldog Gin, Averna, Frangelico, and Espolòn.

Its business model relies on a multi-brand strategy, with each label positioned for distinct consumer segments and distributed through international networks, giving the group exposure across both premium and mainstream price tiers in the global spirits market.

Headlines to Watch Out For
  • Courvoisier cognac acquisition expands US premium spirits exposure
  • Aperol Spritz demand sensitive to European summer weather volatility
  • Deleveraging post-acquisition limits near-term capital returns
Piotroski VR-10 (Strict) 7.5
Net Income: 268.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.03 > 0.02 and ΔFCF/TA 0.75 > 1.0
NWC/Revenue: 62.20% < 20% (prev 71.70%; Δ -9.49% < -1%)
CFO/TA 0.07 > 3% & CFO 562.3m > Net Income 268.9m
Net Debt (2.05b) to EBITDA (699.0m): 2.93 < 3
Current Ratio: 2.58 > 1.5 & < 3
Outstanding Shares: last quarter (1.20b) vs 12m ago -3.94% < -2%
Gross Margin: 60.87% > 18% (prev 60.41%; Δ 0.46% > 0.5%)
Asset Turnover: 37.22% > 50% (prev 27.33%; Δ 9.89% > 0%)
Interest Coverage Ratio: 7.31 > 6 (EBIT TTM 553.6m / Interest Expense TTM 75.7m)
Altman Z'' 4.25
A: 0.23 (Total Current Assets 3.08b - Total Current Liabilities 1.19b) / Total Assets 8.28b
B: 0.41 (Retained Earnings 3.36b / Total Assets 8.28b)
C: 0.07 (EBIT TTM 553.6m / Avg Total Assets 8.15b)
D: 0.93 (Book Value of Equity 3.99b / Total Liabilities 4.29b)
Altman-Z'' = 4.25 = AA
Beneish M -2.99
DSRI: 0.77 (Receivables 513.0m/481.9m, Revenue 3.04b/2.19b)
GMI: 0.99 (GM 60.41% / 60.87%)
AQI: 0.93 (AQ_t 0.44 / AQ_t-1 0.47)
SGI: 1.38 (Revenue 3.04b / 2.19b)
TATA: -0.04 (NI 268.9m - CFO 562.3m) / TA 8.28b)
Beneish M = -2.99 (Cap -4..+1) = A
What is the price of CPR shares?

As of September 19, 2026, the stock is trading at EUR 5.90 with a total of 7,909,045 shares traded. Over the past week, the price has changed by +3.08%, over one month by +1.03%, over three months by +8.10% and over the past year by +5.91%.

Current recommended Stop Loss: 5.50 (which is 6.8% or 3.1 ATR below the current price).

Is CPR a buy, sell or hold?

Davide Campari-Milano has no consensus analysts rating.

Davide Campari-Milano (CPR) - Fundamental Data Overview as of 17 September 2026
Market Cap USD = 8.29b (7.22b EUR * 1.1476 EUR.USD)
P/E Trailing = 26.1826
P/E Forward = 15.0602
P/S = 2.3796
P/B = 1.8111
P/EG = 1.4877
Revenue TTM = 3.04b EUR
EBIT TTM = 553.6m EUR
EBITDA TTM = 699.0m EUR
Long Term Debt = 2.38b EUR (from longTermDebt, last quarter)
Short Term Debt = 255.0m EUR (from shortTermDebt, last quarter)
Debt = 2.76b EUR (from shortLongTermDebtTotal, last quarter) + Leases 72.0m
Net Debt = 2.05b EUR (calculated: Debt 2.76b - CCE 712.0m)
Enterprise Value = 9.27b EUR (7.22b + Debt 2.76b - CCE 712.0m)
Interest Coverage Ratio = 7.31 (Ebit TTM 553.6m / Interest Expense TTM 75.7m)
EV/FCF = 33.23x (Enterprise Value 9.27b / FCF TTM 279.0m)
FCF Yield = 3.01% (FCF TTM 279.0m / Enterprise Value 9.27b)
FCF Margin = 9.19% (FCF TTM 279.0m / Revenue TTM 3.04b)
Net Margin = 8.86% (Net Income TTM 268.9m / Revenue TTM 3.04b)
Gross Margin = 60.87% ((Revenue TTM 3.04b - Cost of Revenue TTM 1.19b) / Revenue TTM)
Gross Margin QoQ = 60.65% (prev 61.09%)
Tobins Q-Ratio = 1.12 (Enterprise Value 9.27b / Total Assets 8.28b)
Interest Expense / Debt = 2.74% (Interest Expense 75.7m / Debt 2.76b)
Taxrate = 32.09% (121.1m / 377.4m)
NOPAT = 376.0m (EBIT 553.6m * (1 - 32.09%))
Current Ratio = 2.58 (Total Current Assets 3.08b / Total Current Liabilities 1.19b)
Debt / Equity = 0.69 (Debt 2.76b / totalStockholderEquity, last quarter 3.99b)
Debt / EBITDA = 2.93 (Net Debt 2.05b / EBITDA 699.0m)
Debt / FCF = 7.34 (Net Debt 2.05b / FCF TTM 279.0m)
Total Stockholder Equity = 3.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.30% (Net Income 268.9m / Total Assets 8.28b)
RoE = 6.98% (Net Income TTM 268.9m / Total Stockholder Equity 3.85b)
RoCE = 8.88% (EBIT 553.6m / Capital Employed (Equity 3.85b + L.T.Debt 2.38b))
RoIC = 5.23% (NOPAT 376.0m / Invested Capital 7.19b)
WACC = 4.15% (E(7.22b)/V(9.98b) * Re(5.02%) + D(2.76b)/V(9.98b) * Rd(2.74%) * (1-Tc(0.32)))
Discount Rate = 5.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 74.90 | Cagr: 2.81%
[DCF] Terminal Value 77.97% ; FCFF base≈251.6m ; Y1≈288.4m ; Y5≈424.4m
[DCF] Fair Price = 3.62 (EV 6.39b - Net Debt 2.05b = Equity 4.34b / Shares 1.20b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 86.27 | Revenue CAGR: 7.77% | SUE: 2.01 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.32 | Chg30d=-0.22% | Revisions=+72% | GrowthEPS=-0.7% | GrowthRev=+0.4%
EPS next Year (2027-12-31): EPS=0.35 | Chg30d=-0.17% | Revisions=+35% | GrowthEPS=+10.5% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: +57% (up=26, down=6)